Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Neurobiol Dis. 2017 Sep 18;109(Pt A):1–10. doi: 10.1016/j.nbd.2017.09.007

Figure 2. Optogenetic inhibition of the DG with iLMO2 decreases seizure duration.

Figure 2

(A) iLMO2 (green) was expressed bilaterally in the DG of the hippocampus. Scale bar: 1 mm. (B) iLMO2 does not co-localize with GAD67 (red), indicating that its expression is restricted from GABAergic cells and limited to the granule cells. Arrow: GAD67+ cell with no iLMO2 expression. Scale bar: 10μm. The latency to first twitch (C) or seizure severity (E) was not significantly increased or decreased, respectively, by CTZ compared to vehicle while seizure duration (D) was significantly reduced (*p<0.05, n=10 animals per treatment, Student’s t-test). CTZ had no effect in halorhodopsin (NpHR) expressing control animals. (F) Mean Racine scores over time after PTZ injection. Error bars indicate SEM.